1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Germany >
  5. Promethera Biosciences SA Acquires Baliopharm AG

M&A Deal Summary

Promethera Biosciences SA Acquires Baliopharm AG

On April 10, 2018, Promethera Biosciences SA acquired life science company Baliopharm AG

Acquisition Highlights
  • This is Promethera Biosciences SA’s 1st transaction in the Life Science sector.
  • This is Promethera Biosciences SA’s 1st transaction in Germany.

M&A Deal Summary
Date 2018-04-10
Target Baliopharm AG
Sector Life Science
Buyer(s) Promethera Biosciences SA
Deal Type Add-on Acquisition

Target

Baliopharm AG

Basel, Germany
Baliopharm AG is a biotechnology company focusing on the development of novel therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis, Crohn`s disease, psoriasis and multiple sclerosis, and for cancer.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Promethera Biosciences SA

Mont-Saint-Guibert, Belgium
Category Company
Sector Medical Products
DESCRIPTION

Promethera Biosciences SA is a provider of clinical program to discovers liver diseases and the leader in liver cell-based medicines. Promethera Biosciences is based in Mont-Saint-Guibert, Belgium.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Germany M&A 1 of 1
Year: 2018 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal